A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

  • days left to enroll
  • participants needed
  • sponsor
    Azura Ophthalmics
Updated on 24 October 2021
dry eye syndrome
corrected visual acuity
eye disease
meibomian gland dysfunction
evaporative dry eye syndrome
meibomian gland obstruction


AZ201801 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)


AZ201801 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study carried out in 2 sequentially overlapping cohorts evaluating the safety, efficacy and tolerability of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)

Condition Dry eye syndrome, Keratoconjunctivitis Sicca, Meibomian Gland Dysfunction, Dry Eyes, eye dryness, dry eye
Treatment AZR-MD-001 Low Dose, AZR-MD-001 Mid Dose, AZR-MD-001 High Dose, AZR-MD-001 Vehicle
Clinical Study IdentifierNCT03652051
SponsorAzura Ophthalmics
Last Modified on24 October 2021


Yes No Not Sure

Inclusion Criteria

Male or female, 18 years of age or older
Best-corrected visual acuity (BCVA) of 20/40 or better (Snellen equivalent), using the logarithm of the minimum angle of resolution (LogMAR) in each eye
Evidence of meibomian gland obstruction
Reported dry eye signs and symptoms within the past 3 months

Exclusion Criteria

Uncontrolled ocular disease (except for MGD and dry eye disease/keratoconjunctivitis sicca) or uncontrolled systemic disease
Glaucoma, ocular hypertension, or intraocular pressure (IOP) in either eye at screening 24 mm Hg or has planned insertion/removal of glaucoma filtration shunts/devices during the study
Corneal abnormality or disorder that impacts normal spreading of the tear film or corneal integrity
BCVA worse than 20/40 in either eye
Current use of punctal plugs, anticipated insertion during the study, or a history of punctal cautery in either eye
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note